1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
M. Kashani-Sabet has an ownership interest in Melanoma Diagnostics.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Osteopontin as a molecular prognostic marker for melanoma
Article first published online: 19 NOV 2007
DOI: 10.1002/cncr.23147
Copyright © 2007 American Cancer Society
Additional Information
How to Cite
Rangel, J., Nosrati, M., Torabian, S., Shaikh, L., Leong, S. P. L., Haqq, C., Miller, J. R., Sagebiel, R. W. and Kashani-Sabet, M. (2008), Osteopontin as a molecular prognostic marker for melanoma. Cancer, 112: 144–150. doi: 10.1002/cncr.23147
- †
M. Kashani-Sabet has an ownership interest in Melanoma Diagnostics.
- ‡
Fax (415) 353-9505
Publication History
- Issue published online: 17 DEC 2007
- Article first published online: 19 NOV 2007
- Manuscript Accepted: 30 JUL 2007
- Manuscript Revised: 29 JUL 2007
- Manuscript Received: 19 APR 2007
Funded by
- Herschel and Diana Zackheim Endowment Fund
- American Cancer Society Research Scholar. Grant Number: RSG-03-247-01-MGO
- United States Public Health Service. Grant Number: CA114337
REFERENCES
- 1,. Role of osteopontin in tumour progression. Br J Cancer. 2004; 90: 877–881.
- 2,,. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16: 79–87.
- 3,,,,. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature. 1983; 302: 714–715.
- 4,,, et al. Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer. 1990; 46: 13313–13317.
- 5,,. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumor model. Oncogene. 1996; 13: 97–104.
- 6,,, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002; 62: 3417–3427.
- 7,,, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002; 94: 513–521.
- 8,,, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004; 10: 184–190.
- 9,,. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001; 276: 44926–44935.
- 10,,, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005; 124: 1044–1052.
- 11,,, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000; 406: 536–540.
- 12,,, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 2005; 102: 6092–607.
- 13,,. Whole genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005; 4: 1018–1029.
- 14,,, et al. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol. 2006; 24: 4565–459.
- 15,,, et al. NF-kappa B in the vascular progression of melanoma. J Clin Oncol. 2004; 22: 617–623.
- 16,,, et al. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol. 2002; 20: 1826–1831.
- 17,,, et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001; 137: 1169–1173.
- 18. A new rank test against ordered alternatives in K-sample problems. Biometrical J. 1988; 30: 87–92.
- 19,,, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 3622–3634.
- 20,,, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 3635–3648.
- 21,. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B/IKK signaling pathways, and curcumin (diferulolylmethane) downregulates these pathways. J Biol Chem. 2003; 278: 14487–14497.
- 22,,, et al. Constitutive activation of AKT/protein kinase B in melanoma leads to upregulation of nuclear factor-kappa B and tumor progression. Cancer Res. 2002; 62: 7335–7342.
- 23,,, et al. Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc Natl Acad Sci USA. 2002; 99: 3878–3883.
- 24,,, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 2007; 13: 806–815.
- 25,,, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res. 2007; 67: 3450–3460.
- 26,,, et al. Markers and tissue resources for melanoma: meeting report. Cancer Res. 2006; 66: 10652–10657.
- 27,,, et al. Role of the integrin protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006; 169: 233–246.